Stanford Downgrades ViroPharma (VPHM) to Hold
More News related to VPHM
- ViroPharma and Lev Receive Hart-Scott-Rodino Clearance from the Federal Trade Commission
- ViroPharma and Lev Receive Hart-Scott-Rodino Clearance from The Federal Trade Commission
- ViroPharma to Present at Three September Healthcare Conferences
- Lev Reports Second Quarter 2008 Financial Results
- Pre-Open Movers 7/30: Elan (ELN) Sinks On Drug Data; Buffalo Wild Wings (BWLD) Up on Results
More News related to Downgrades
- Raymond James Downgrades 8 Restaurant Stocks Today
- Merrill Lynch Downgrades General Dynamics (GD) to Neutral
- Deutshe Bank Downgrades Cavium Networks (CAVM) to Hold
- Sandler O'Neill Downgrades Boston Private (BPFH) to Sell
- Raymond James Downgrades Hibbet Sports (HIBB) to Market Perform
Stanford Group downgrades ViroPharma (Nasdaq: VPHM) from Buy to Hold.
ViroPharma Incorporated, a biopharmaceutical company, engages in the development and commercialization of products that address serious infectious diseases treated by physician specialists and in hospital settings in the United States and internationally.
Related Categories
DowngradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
